Zymeworks (ZYME) News Today $13.88 -0.11 (-0.79%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Wednesday's Insider Activity: Top Buys and Sells in US StocksJanuary 16 at 12:08 PM | msn.comZymeworks (NYSE:ZYME) Shares Gap Up Following Insider Buying ActivityZymeworks (NYSE:ZYME) Shares Gap Up Following Insider Buying ActivityJanuary 16 at 10:14 AM | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Purchases $546,796.29 in StockJanuary 16 at 6:20 AM | insidertrades.comEcor1 Capital, Llc Buys 39,029 Shares of Zymeworks Inc. (NYSE:ZYME) StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc bought 39,029 shares of the stock in a transaction dated Wednesday, January 15th. The stock was bought at an average price of $14.01 per share, with a total value of $546,796.29. Following the acquisition, the director now owns 15,578,732 shares in the company, valued at approximately $218,258,035.32. This represents a 0.25 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.January 15 at 7:34 PM | marketbeat.comInsider Buying: Zymeworks Inc. (NYSE:ZYME) Director Acquires 74,125 Shares of StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc acquired 74,125 shares of the company's stock in a transaction that occurred on Monday, January 13th. The stock was acquired at an average cost of $13.39 per share, for a total transaction of $992,533.75. Following the acquisition, the director now owns 15,485,203 shares of the company's stock, valued at $207,346,868.17. The trade was a 0.48 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.January 15 at 7:34 PM | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Acquires $295,765.47 in StockJanuary 13, 2025 | americanbankingnews.comBig Biotech Fund Loads Up on a Stock That Surged in 2024, and a LoserJanuary 12, 2025 | msn.comEcor1 Capital, Llc Purchases 21,021 Shares of Zymeworks Inc. (NYSE:ZYME) StockJanuary 11, 2025 | insidertrades.comEcor1 Capital, Llc Purchases 21,021 Shares of Zymeworks Inc. (NYSE:ZYME) StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc acquired 21,021 shares of the company's stock in a transaction dated Wednesday, January 8th. The stock was acquired at an average cost of $14.07 per share, for a total transaction of $295,765.47. Following the completion of the purchase, the director now directly owns 15,206,980 shares in the company, valued at $213,962,208.60. This trade represents a 0.14 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.January 10, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 204,098 Shares of StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc acquired 204,098 shares of the company's stock in a transaction that occurred on Friday, January 10th. The shares were acquired at an average cost of $13.13 per share, with a total value of $2,679,806.74. Following the purchase, the director now owns 15,411,078 shares in the company, valued at $202,347,454.14. This represents a 1.34 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.January 10, 2025 | marketbeat.comZymeworks in Focus for Insider Activity: Catalysts AheadJanuary 10, 2025 | insidertrades.comZymeworks (ZYME) Receives a Buy from Stifel NicolausJanuary 10, 2025 | markets.businessinsider.comZymeworks Inc.: Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026January 8, 2025 | finanznachrichten.deZymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026January 8, 2025 | globenewswire.comJeffrey T. L. Smith Sells 11,110 Shares of Zymeworks Inc. (NYSE:ZYME) StockJanuary 8, 2025 | americanbankingnews.comZymeworks Inc. (NYSE:ZYME) EVP Jeffrey T. L. Smith Sells 11,110 SharesJanuary 7, 2025 | insidertrades.comInsider Selling: Zymeworks Inc. (NYSE:ZYME) EVP Sells 11,110 Shares of StockZymeworks Inc. (NYSE:ZYME - Get Free Report) EVP Jeffrey T. L. Smith sold 11,110 shares of Zymeworks stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $14.92, for a total transaction of $165,761.20. Following the sale, the executive vice president now owns 8,890 shares in the company, valued at approximately $132,638.80. This trade represents a 55.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.January 6, 2025 | marketbeat.comPaul Andrew Moore Sells 21,200 Shares of Zymeworks Inc. (NYSE:ZYME) StockZymeworks Inc. (NYSE:ZYME - Get Free Report) insider Paul Andrew Moore sold 21,200 shares of the business's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $14.92, for a total value of $316,304.00. Following the sale, the insider now directly owns 14,741 shares in the company, valued at $219,935.72. This trade represents a 58.99 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.January 6, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) CEO Sells $854,781.72 in StockZymeworks Inc. (NYSE:ZYME - Get Free Report) CEO Kenneth Galbraith sold 57,291 shares of Zymeworks stock in a transaction on Monday, January 6th. The stock was sold at an average price of $14.92, for a total transaction of $854,781.72. Following the transaction, the chief executive officer now owns 47,543 shares in the company, valued at approximately $709,341.56. This trade represents a 54.65 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.January 6, 2025 | marketbeat.comLandsea Homes, LandBridge, and More Stocks See Action From Activist InvestorsJanuary 3, 2025 | msn.comZymeworks (NYSE:ZYME) Shares Gap Up on Insider Buying ActivityZymeworks (NYSE:ZYME) Shares Gap Up Following Insider Buying ActivityJanuary 3, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 58,988 SharesJanuary 3, 2025 | insidertrades.comInsider Buying: Zymeworks Inc. (NYSE:ZYME) Director Buys 58,988 Shares of StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc purchased 58,988 shares of Zymeworks stock in a transaction that occurred on Monday, December 30th. The shares were bought at an average price of $14.47 per share, for a total transaction of $853,556.36. Following the completion of the transaction, the director now owns 14,881,578 shares in the company, valued at $215,336,433.66. The trade was a 0.40 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.January 2, 2025 | marketbeat.comEcor1 Capital, Llc Buys 157,880 Shares of Zymeworks Inc. (NYSE:ZYME) StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc purchased 157,880 shares of the stock in a transaction dated Thursday, January 2nd. The stock was purchased at an average price of $14.78 per share, for a total transaction of $2,333,466.40. Following the completion of the acquisition, the director now directly owns 15,185,959 shares in the company, valued at approximately $224,448,474.02. This represents a 1.05 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website.January 2, 2025 | marketbeat.comEcor1 Capital, Llc Purchases 11,958 Shares of Zymeworks Inc. (NYSE:ZYME) StockDecember 28, 2024 | insidertrades.comZymeworks Inc. (NYSE:ZYME) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Zymeworks Inc. (NYSE:ZYME - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven brokerages that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, four have assigned a buy recommendaDecember 28, 2024 | marketbeat.comInsider Buying: Zymeworks Inc. (NYSE:ZYME) Director Purchases 11,958 Shares of StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc acquired 11,958 shares of the firm's stock in a transaction on Tuesday, December 24th. The stock was purchased at an average cost of $14.12 per share, for a total transaction of $168,846.96. Following the completion of the acquisition, the director now owns 14,704,239 shares in the company, valued at approximately $207,623,854.68. This represents a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.December 27, 2024 | marketbeat.comInsider Buying: Zymeworks Inc. (NYSE:ZYME) Director Acquires 16,692 Shares of StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc bought 16,692 shares of Zymeworks stock in a transaction dated Thursday, December 26th. The stock was purchased at an average cost of $14.38 per share, with a total value of $240,030.96. Following the completion of the acquisition, the director now directly owns 14,720,931 shares in the company, valued at approximately $211,686,987.78. The trade was a 0.11 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.December 27, 2024 | marketbeat.comBarclays PLC Raises Stake in Zymeworks Inc. (NYSE:ZYME)Barclays PLC lifted its position in Zymeworks Inc. (NYSE:ZYME - Free Report) by 476.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 154,384 shares of the company's stock after purchaDecember 27, 2024 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Shares Bought by State Street CorpState Street Corp lifted its holdings in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 6.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,171,777 shares of the company's stock after buying an additional 67,401 shares during the period. StateDecember 25, 2024 | marketbeat.comZymeworks (NYSE:ZYME) Shares Down 2.4% - Here's WhyZymeworks (NYSE:ZYME) Stock Price Down 2.4% - Here's WhyDecember 20, 2024 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Shares Sold by Y Intercept Hong Kong LtdY Intercept Hong Kong Ltd cut its holdings in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 79.9% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,724 shares of the company's stock after selling 46,586 shares duDecember 20, 2024 | marketbeat.comZymeworks price target raised to $14 from $12 at Wells FargoDecember 20, 2024 | markets.businessinsider.comDeep Dive Into Zymeworks Stock: Analyst Perspectives (10 Ratings)December 20, 2024 | benzinga.comZymeworks (NYSE:ZYME) Stock Price Up 4.3% Following Analyst UpgradeZymeworks (NYSE:ZYME) Stock Price Up 4.3% Following Analyst UpgradeDecember 19, 2024 | marketbeat.comWells Fargo & Company Issues Positive Forecast for Zymeworks (NYSE:ZYME) Stock PriceWells Fargo & Company lifted their target price on shares of Zymeworks from $12.00 to $14.00 and gave the company an "equal weight" rating in a report on Thursday.December 19, 2024 | marketbeat.comZymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of ScheduleDecember 19, 2024 | seekingalpha.comZymeworks Inc. (NYSE:ZYME) Stock Holdings Trimmed by Wellington Management Group LLPWellington Management Group LLP lessened its position in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 27.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 243,189 shares of the company's stock aDecember 18, 2024 | marketbeat.comJP Morgan Upgrades Zymeworks (ZYME)December 17, 2024 | msn.comZymeworks (NYSE:ZYME) Shares Gap Up - Here's WhyZymeworks (NYSE:ZYME) Shares Gap Up - Here's What HappenedDecember 16, 2024 | marketbeat.comZymeworks (NYSE:ZYME) Upgraded at JPMorgan Chase & Co.JPMorgan Chase & Co. raised Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 price objective for the company in a report on Monday.December 16, 2024 | marketbeat.comZymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth PlansDecember 13, 2024 | finance.yahoo.comZymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory DiseasesDecember 12, 2024 | markets.businessinsider.comZymeworks Inc. (NYSE:ZYME) Shares Sold by Point72 Asset Management L.P.Point72 Asset Management L.P. lessened its holdings in Zymeworks Inc. (NYSE:ZYME - Free Report) by 74.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,583 shares of the company's stock after selDecember 12, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Has $6.56 Million Stake in Zymeworks Inc. (NYSE:ZYME)Jacobs Levy Equity Management Inc. reduced its position in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 19.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 522,640 shares of the company's stock after selliDecember 6, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stake in Zymeworks Inc. (NYSE:ZYME)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its holdings in Zymeworks Inc. (NYSE:ZYME - Free Report) by 19.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,524,084 shDecember 6, 2024 | marketbeat.comRedmile Group LLC Sells 109,126 Shares of Zymeworks Inc. (NYSE:ZYME)Redmile Group LLC decreased its stake in Zymeworks Inc. (NYSE:ZYME - Free Report) by 2.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,101,911 shares of the company's stock after selDecember 5, 2024 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Zymeworks Inc. (NYSE:ZYME - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six brokerages that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has iDecember 3, 2024 | marketbeat.comVestal Point Capital LP Boosts Stake in Zymeworks Inc. (NYSE:ZYME)Vestal Point Capital LP increased its stake in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 39.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 615,000 shares of the company's stock after buying an aNovember 29, 2024 | marketbeat.comZymeworks Gains Buy Rating Amid FDA Approval and Market Expansion Potential for ZanidatamabNovember 25, 2024 | markets.businessinsider.com Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYME Media Mentions By Week ZYME Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZYME News Sentiment▼1.080.57▲Average Medical News Sentiment ZYME News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZYME Articles This Week▼94▲ZYME Articles Average Week Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BHVN News VRNA News ACLX News CRNX News APLS News PTCT News RNA News RYTM News IMVT News ACAD News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ZYME) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZYME Stock Alerts